In liver cancer, Zhang et al. reported that dihydromyricetin inhibits the migration and invasion of hepatoma cells by reducing MMP-9 expression via a mechanism that is dependent on the upregulation of PRKCD [34]. Here, PRKCD is linked to liver cancer.